Acrivon Therapeutics, Inc. (ACRV) shareholders
Close on Nov 17, 2026Market cap $61.28MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Rajeev Shah Joint filing with RA Capital Management, L.P. (28.80%), Peter Kolchinsky (28.80%) and 1 more | 12,284,906 | 28.80% | 13D (active) amendment | Apr 22, 2026 |
| Wiaczeslaw Smolokowski | 3,848,632 | – | 13G (passive) amendment | Jun 30, 2024 |
| Perceptive Advisors LLC Joint filing with Joseph Edelman (9.90%), Perceptive Life Sciences Master Fund, Ltd. (9.90%) | 3,104,139 | 9.90% | 13G (passive) amendment | Apr 29, 2025 |
| Sands Capital Life Sciences Pulse Fund II, L.P. Joint filing with Sands Capital Alternatives, LLC (5.30%), Sands Frank M. (5.30%) | 2,289,271 | 5.30% | 13G (passive) amendment | Jun 30, 2026 |
| Sands Capital Alternatives, LLC Joint filing with Sands Capital Life Sciences Pulse Fund II, L.P. (6.80%), Sands Frank M. (6.80%) | 2,122,605 | 6.80% | 13G (passive) amendment | Jun 30, 2025 |
| Kenneth Griffin | 1,721,867 | 5.50% | 13G (passive) | Nov 14, 2025 |
| Sands Capital Ventures, LLC Joint filing with Sands Capital Life Sciences Pulse Fund II, L.P. (7.40%), Frank M. Sands (7.40%) | 1,652,605 | 7.40% | 13G (passive) amendment | Dec 31, 2023 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ACRV | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 12,229,396 | 28.54% | $21.77M | +3,888,888 | 0.19% |
| Sands Capital Ventures, LLC | 2,289,271 | 5.34% | $4.07M | +166,666 | 0.66% |
| Acadian Asset Management LLC | 1,165,119 | 2.72% | $2.07M | +319,146 | 0.00% |
| Vanguard Capital Management LLC | 952,008 | 2.22% | $1.69M | +229,973 | 0.00% |
| Wellington Management Group Llp | 888,130 | 2.07% | $1.58M | – | 0.00% |
| Renaissance Technologies LLC | 758,863 | 1.77% | $1.35M | +423 | 0.00% |
| Two Sigma Investments, LP | 641,498 | 1.50% | $1.14M | +252,103 | 0.00% |
| Marshall Wace, Llp | 531,856 | 1.24% | $946.70K | −28,580 | 0.00% |
| Bridgeway Capital Management, LLC | 378,900 | 0.88% | $674.44K | +220,000 | 0.01% |
| Geode Capital Management, LLC | 265,241 | 0.62% | $472.27K | +28,850 | 0.00% |
| BlackRock, Inc. | 239,112 | 0.56% | $425.62K | +30,173 | 0.00% |
| Gsa Capital Partners Llp | 200,415 | 0.47% | $357.00K | +13,699 | 0.02% |
| Vanguard Fiduciary Trust Co | 184,128 | 0.43% | $327.75K | +76,599 | 0.00% |
| XTX Topco Ltd | 178,239 | 0.42% | $317.27K | +111,357 | 0.00% |
| Jane Street Group, LLC | 74,648 | 0.17% | $132.87K | −165,043 | 0.00% |
| Northern Trust Corp | 67,202 | 0.16% | $119.62K | +18,300 | 0.00% |
| State Street Corp | 67,145 | 0.16% | $119.52K | – | 0.00% |
| UBS Group AG | 43,850 | 0.10% | $78.05K | +9,216 | 0.00% |
| Citadel Advisors LLC | 41,276 | 0.10% | $73.47K | New | 0.00% |
| Dimensional Fund Advisors LP | 29,332 | 0.07% | $52.21K | +10,968 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 46 | 21M | 49.9% | 6 / 21 | 9 / 4 | 5M | 0M |
| Q1 2026 | 44 | 16M | 37.9% | 10 / 11 | 11 / 13 | 2M | 3M |
| Q4 2025 | 48 | 19M | 43.4% | 8 / 16 | 10 / 8 | 2M | 1M |
| Q3 2025 | 48 | 18M | 40.9% | 6 / 11 | 19 / 11 | 1M | 2M |
| Q2 2025 | 53 | 18M | 41.5% | 15 / 11 | 17 / 25 | 2M | 7M |
| Q1 2025 | 63 | 23M | 52.6% | 8 / 17 | 22 / 7 | 0M | 1M |
| Q4 2024 | 63 | 23M | 54.3% | 13 / 18 | 15 / 5 | 1M | 1M |
| Q3 2024 | 55 | 23M | 54.0% | 8 / 17 | 14 / 7 | 2M | 1M |
| Q2 2024 | 55 | 23M | 54.8% | 12 / 24 | 7 / 5 | 8M | 0M |
| Q1 2024 | 48 | 15M | 35.7% | 12 / 15 | 8 / 6 | 1M | 1M |
| Q4 2023 | 42 | 15M | 35.9% | 3 / 16 | 9 / 4 | 0M | 0M |
| Q3 2023 | 43 | 15M | 35.2% | 4 / 15 | 12 / 1 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
14 funds held ACRV in Q2 2026, 63% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ACRV | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 545,541 | 1.27% | $971.06K | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 389,575 | 0.91% | $693.44K | 0.00% | Jun 30, 2026 |
| Ultra-Small Company Fund | 316,000 | 0.74% | $562.48K | 0.57% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 111,335 | 0.26% | $178.14K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 73,869 | 0.17% | $131.49K | 0.01% | Jun 30, 2026 |
| Ultra-Small Company Market Fund | 58,000 | 0.14% | $103.24K | 0.07% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 27,696 | 0.06% | $44.31K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 24,809 | 0.06% | $39.69K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 18,053 | 0.04% | $28.88K | 0.00% | May 31, 2026 |
| Vanguard Balanced Index Fund | 16,892 | 0.04% | $30.07K | 0.00% | Jun 30, 2026 |
| 1290 VT Micro Cap Portfolio | 4,941 | 0.01% | $8.79K | 0.00% | Jun 30, 2026 |
| Blackstone Alternative Multi-Strategy Fund | 2,500 | 0.01% | $4.45K | 0.00% | Jun 30, 2026 |
| Total Stock Market Index Trust | 937 | 0.00% | $1.67K | 0.00% | Jun 30, 2026 |
| Knights of Columbus U.S. ALL CAP INDEX FUND | 115 | 0.00% | $173 | 0.00% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Kristina Masson | EVP - Business Operations, Director | 2,629,947 | 6.14% | Aug 27, 2026 |
| Peter Blume-Jensen | President and CEO, Director | 2,615,911 | 6.10% | Aug 27, 2026 |
| Mary Miller | Chief Legal Officer | 81,202 | 0.19% | Oct 26, 2026 |
| Michaela Levin | Chief Business Officer | 30,000 | 0.07% | Sep 2, 2026 |
| Eric Devroe | Chief Operating Officer | 146,349 | 0.34% | Aug 20, 2026 |
| Katharine Peterson | Chief Accounting Officer | 18,033 | 0.04% | Aug 20, 2026 |
| Erick Gamelin | Chief Development Officer | 52,592 | 0.12% | Aug 20, 2026 |
| Adam D. Levy | Chief Financial Officer | 66,008 | 0.15% | Aug 6, 2026 |
| Mansoor Raza Mirza | Chief Medical Officer | 38,817 | 0.09% | May 20, 2026 |
| Jean-Marie Cuillerot | Chief Medical Officer | – | – | Mar 4, 2025 |
| Rasmus Holm-Jorgensen | Chief Financial Officer | 26,088 | 0.06% | Mar 4, 2025 |
| Santhosh Palani | Director | 9,366 | 0.02% | Jun 22, 2026 |
| Rajeev M. Shah | Director, 10% owner | – | – | Jun 22, 2026 |
| Peter Kolchinsky | Director, 10% owner | – | – | Jun 22, 2026 |
| Ra Capital Management, L.P. | Director, 10% owner | – | – | Jun 22, 2026 |
| RA Capital Nexus Fund II, L.P. | Director | 9,366 | 0.02% | Jun 22, 2026 |
| Charles M. Baum | Director | 9,366 | 0.02% | Jun 22, 2026 |
| Derek DiRocco | Director | 9,366 | 0.02% | Jun 22, 2026 |
| Capital Healthcare Fund LP RA | Director, 10% owner | 7,914,206 | 18.47% | Jun 22, 2026 |
| Sharon Shacham | Director | 9,366 | 0.02% | Jun 22, 2026 |
| Michael John Tomsicek | Director | 9,366 | 0.02% | Jun 22, 2026 |
| Ivana Magovcevic-Liebisch | Director | 9,366 | 0.02% | Jun 22, 2026 |
| Joseph Edelman | 10% owner | 3,007,858 | 7.02% | May 1, 2025 |
| Advisors Llc Perceptive | 10% owner | 3,104,139 | 7.24% | May 1, 2025 |
| Life Sciences Master Fund Ltd Perceptive | 10% owner | 5,360,858 | 12.51% | May 1, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Mary Miller Chief Legal Officer | Oct 22, 2026 | Sale | −513 | $1.84 | $944 | 81,202 |
| Mary Miller Chief Legal Officer | Oct 5, 2026 | Sale | −294 | $1.99 | $585 | 81,715 |
| Michaela Levin Chief Business Officer | Aug 31, 2026 | Award | +30,000 | – | – | 30,000 |
| Peter Blume-Jensen President and CEO, Director | Aug 25, 2026 | Sale | −14,036 | $2.21 | $31.02K | 2,230,052 |
| Erick Gamelin Chief Development Officer | Aug 18, 2026 | Sale | −400 | $2.01 | $804 | 52,592 |
| Mary Miller Chief Legal Officer | Aug 18, 2026 | Sale | −185 | $2.01 | $372 | 82,009 |
| Kristina Masson EVP - Business Operations, Director | Aug 18, 2026 | Sale | −484 | $2.01 | $973 | 385,859 |
| Kristina Masson EVP - Business Operations, Director | Aug 18, 2026 | Sale | −1,229 | $2.01 | $2.47K | 2,244,088 |
| Katharine Peterson Chief Accounting Officer | Aug 18, 2026 | Sale | −101 | $2.01 | $203 | 18,033 |
| Eric Devroe Chief Operating Officer | Aug 18, 2026 | Sale | −604 | $2.01 | $1.21K | 146,349 |
| Adam D. Levy Chief Financial Officer | Aug 4, 2026 | Sale | −1,142 | $1.57 | $1.79K | 66,008 |
| Mary Miller Chief Legal Officer | Jul 21, 2026 | Sale | −573 | $1.76 | $1.01K | 82,194 |
| Kristina Masson EVP - Business Operations, Director | May 21, 2026 | Tax withholding | −13,729 | $1.79 | $24.57K | 2,245,317 |
| Peter Blume-Jensen President and CEO, Director | May 18, 2026 | Award | +180,095 | – | – | 2,259,046 |
| Peter Blume-Jensen President and CEO, Director | May 18, 2026 | Award | +72,706 | – | – | 386,343 |
| Katharine Peterson Chief Accounting Officer | May 18, 2026 | Award | +14,227 | – | – | 18,134 |
| Erick Gamelin Chief Development Officer | May 18, 2026 | Award | +38,584 | – | – | 52,992 |
| Derek DiRocco Director | May 18, 2026 | Award | +9,366 | – | – | 9,366 |
| Michael John Tomsicek Director | May 18, 2026 | Award | +9,366 | – | – | 9,366 |
| Mary Miller Chief Legal Officer | May 18, 2026 | Award | +49,830 | – | – | 82,767 |
| Ivana Magovcevic-Liebisch Director | May 18, 2026 | Award | +9,366 | – | – | 9,366 |
| Eric Devroe Chief Operating Officer | May 18, 2026 | Award | +72,981 | – | – | 146,953 |
| Adam D. Levy Chief Financial Officer | May 18, 2026 | Award | +46,167 | – | – | 67,150 |
| Santhosh Palani Director | May 18, 2026 | Award | +9,366 | – | – | 9,366 |
| RA Capital Nexus Fund II, L.P. Director | May 18, 2026 | Award | +9,366 | – | – | 9,366 |
| Mansoor Raza Mirza Chief Medical Officer | May 18, 2026 | Award | +38,817 | – | – | 38,817 |
| Sharon Shacham Director | May 18, 2026 | Award | +9,366 | – | – | 9,366 |
| Charles M. Baum Director | May 18, 2026 | Award | +9,366 | – | – | 9,366 |
| Eric Devroe Chief Operating Officer | May 14, 2026 | Tax withholding | −613 | $1.92 | $1.18K | 73,972 |
| Erick Gamelin Chief Development Officer | May 14, 2026 | Tax withholding | −404 | $1.92 | $776 | 14,408 |
| Mary Miller Chief Legal Officer | May 14, 2026 | Tax withholding | −184 | $1.92 | $353 | 32,937 |
| Katharine Peterson Chief Accounting Officer | May 14, 2026 | Tax withholding | −99 | $1.92 | $190 | 3,907 |
| Peter Blume-Jensen President and CEO, Director | May 14, 2026 | Tax withholding | −490 | $1.92 | $941 | 313,637 |
| Peter Blume-Jensen President and CEO, Director | May 14, 2026 | Tax withholding | −1,253 | $1.92 | $2.41K | 2,078,951 |
| RA Capital Nexus Fund II, L.P. Director | Apr 22, 2026 | Award | +3,888,888 | $1.80 | $7.00M | 11,803,094 |
| Mary Miller Chief Legal Officer | Apr 17, 2026 | Tax withholding | −558 | $1.78 | $993 | 33,121 |
| Peter Blume-Jensen President and CEO, Director | Feb 21, 2026 | Tax withholding | −14,265 | $1.53 | $21.83K | 2,080,204 |
| Erick Gamelin Chief Development Officer | Feb 14, 2026 | Tax withholding | −471 | $1.63 | $768 | 14,812 |
| Katharine Peterson Chief Accounting Officer | Feb 14, 2026 | Tax withholding | −116 | $1.63 | $189 | 4,006 |
| Peter Blume-Jensen President and CEO, Director | Feb 14, 2026 | Tax withholding | −1,302 | $1.63 | $2.12K | 2,094,469 |
| Peter Blume-Jensen President and CEO, Director | Feb 14, 2026 | Tax withholding | −579 | $1.63 | $944 | 314,127 |
| Eric Devroe Chief Operating Officer | Feb 14, 2026 | Tax withholding | −723 | $1.63 | $1.18K | 74,585 |
| Mary Miller Chief Legal Officer | Feb 14, 2026 | Tax withholding | −217 | $1.63 | $354 | 33,679 |
| Mary Miller Chief Legal Officer | Jan 17, 2026 | Tax withholding | −659 | $1.98 | $1.30K | 33,896 |
| Peter Blume-Jensen President and CEO, Director | Jan 14, 2026 | Buy | +49,000 | $1.68 | $82.32K | 2,095,771 |
| Adam D. Levy Chief Financial Officer | Jan 14, 2026 | Buy | +8,832 | $1.70 | $15.01K | 20,983 |
| Eric Devroe Chief Operating Officer | Jan 13, 2026 | Buy | +10,000 | $1.72 | $17.20K | 75,308 |
| Kristina Masson EVP - Business Operations, Director | Nov 21, 2025 | Tax withholding | −19,904 | $2.30 | $45.78K | 2,046,771 |
| Katharine Peterson Chief Accounting Officer | Nov 14, 2025 | Tax withholding | −99 | $2.24 | $222 | 4,122 |
| Kristina Masson EVP - Business Operations, Director | Nov 14, 2025 | Tax withholding | −59,765 | $2.24 | $133.87K | 2,066,675 |
| Kristina Masson EVP - Business Operations, Director | Nov 14, 2025 | Tax withholding | −490 | $2.24 | $1.10K | 314,706 |
| Mary Miller Chief Legal Officer | Nov 14, 2025 | Tax withholding | −184 | $2.24 | $412 | 34,555 |
| Erick Gamelin Chief Development Officer | Nov 14, 2025 | Tax withholding | −403 | $2.24 | $903 | 15,283 |
| Eric Devroe Chief Operating Officer | Nov 14, 2025 | Tax withholding | −613 | $2.24 | $1.37K | 65,308 |
| Mary Miller Chief Legal Officer | Oct 17, 2025 | Tax withholding | −558 | $1.81 | $1.01K | 34,739 |
| Mary Miller Chief Legal Officer | Oct 1, 2025 | Tax withholding | −284 | $1.81 | $514 | 35,297 |
| Kristina Masson EVP - Business Operations, Director | Aug 21, 2025 | Tax withholding | −19,905 | $1.32 | $26.27K | 2,126,440 |
| Eric Devroe Chief Operating Officer | Aug 14, 2025 | Tax withholding | −613 | $1.39 | $852 | 65,921 |
| Katharine Peterson Chief Accounting Officer | Aug 14, 2025 | Tax withholding | −99 | $1.39 | $138 | 4,221 |
| Kristina Masson EVP - Business Operations, Director | Aug 14, 2025 | Tax withholding | −59,766 | $1.39 | $83.07K | 2,146,345 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Acrivon Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 241 shares on Oct 1, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Peter Blume-Jensen Officer, Director | Aug 25, 2026 | 14,036 | $30.60K | Aug 25, 2026 | Settlement of vested RSUs issued under an S-8 Registration Plan |
| Chione Ltd 10% Stockholder | Jun 12, 2023 | 219,259 | $2.73M | Jun 12, 2023 | conversion of shares of series A-1 preferred stock |
See a number that looks wrong?